Lilly Wong

1.6k total citations · 1 hit paper
47 papers, 1.0k citations indexed

About

Lilly Wong is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Lilly Wong has authored 47 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 20 papers in Oncology and 11 papers in Immunology. Recurrent topics in Lilly Wong's work include CAR-T cell therapy research (12 papers), Multiple Myeloma Research and Treatments (9 papers) and Immune Cell Function and Interaction (7 papers). Lilly Wong is often cited by papers focused on CAR-T cell therapy research (12 papers), Multiple Myeloma Research and Treatments (9 papers) and Immune Cell Function and Interaction (7 papers). Lilly Wong collaborates with scholars based in United States, United Kingdom and Spain. Lilly Wong's co-authors include Patricia A. Jennings, Joseph A. Adams, Palmer Taylor, Zoran Radić, Harvey Alan Berman, Roger J. M. Brüggemann, Natilie Hosea, Guochun Jiang, Virgil L. Woods and Bahram Valamehr and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Lilly Wong

46 papers receiving 1.0k citations

Hit Papers

Induced pluripotent stem-cell-derived CD19-directed chime... 2025 2026 2025 10 20 30 40

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lilly Wong United States 19 591 326 208 135 123 47 1.0k
Micah Steffek United States 16 459 0.8× 101 0.3× 363 1.7× 64 0.5× 94 0.8× 20 991
Shiro Soga Japan 16 1.0k 1.7× 132 0.4× 202 1.0× 94 0.7× 67 0.5× 26 1.2k
Qi-Zhuang Ye United States 21 679 1.1× 538 1.7× 73 0.4× 38 0.3× 77 0.6× 42 1.3k
T. Haikarainen Finland 20 660 1.1× 525 1.6× 258 1.2× 16 0.1× 117 1.0× 47 1.3k
Chuanbing Bian China 17 1.2k 2.0× 201 0.6× 82 0.4× 25 0.2× 74 0.6× 24 1.5k
Greg M. Arndt Australia 18 873 1.5× 165 0.5× 134 0.6× 27 0.2× 53 0.4× 45 1.2k
Baoxu Pang Netherlands 12 710 1.2× 232 0.7× 112 0.5× 31 0.2× 58 0.5× 16 1000
Joseph Lee United States 17 1.7k 2.8× 305 0.9× 75 0.4× 43 0.3× 44 0.4× 31 1.9k
Shinwu Jeong United States 24 1.4k 2.3× 207 0.6× 165 0.8× 78 0.6× 45 0.4× 47 2.0k
Tonia J. Buchholz United States 14 874 1.5× 309 0.9× 75 0.4× 242 1.8× 326 2.7× 21 1.1k

Countries citing papers authored by Lilly Wong

Since Specialization
Citations

This map shows the geographic impact of Lilly Wong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lilly Wong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lilly Wong more than expected).

Fields of papers citing papers by Lilly Wong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lilly Wong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lilly Wong. The network helps show where Lilly Wong may publish in the future.

Co-authorship network of co-authors of Lilly Wong

This figure shows the co-authorship network connecting the top 25 collaborators of Lilly Wong. A scholar is included among the top collaborators of Lilly Wong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lilly Wong. Lilly Wong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Strati, Paolo, Januario E. Castro, Aaron M. Goodman, et al.. (2025). Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study. The Lancet Haematology. 12(7). e505–e515. 2 indexed citations
2.
Ghobadi, Armin, Veronika Bachanová, Krish Patel, et al.. (2025). Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. The Lancet. 405(10473). 127–136. 42 indexed citations breakdown →
3.
Tang, Yuyang, Ling Xie, Dajiang Li, et al.. (2025). Persistent type I interferon signaling within the brain of people with HIV on ART with cognitive impairment. PLoS Pathogens. 21(8). e1013411–e1013411.
4.
7.
Li, Dajiang, Lilly Wong, Yuyang Tang, et al.. (2022). Depletion of HIV reservoir by activation of ISR signaling in resting CD4+ T cells. iScience. 26(1). 105743–105743. 5 indexed citations
8.
Wong, Lilly, Zhengyu Wei, Xianwei Wang, et al.. (2022). Microglia-Specific Promoter Activities of HEXB Gene. Frontiers in Cellular Neuroscience. 16. 808598–808598. 11 indexed citations
9.
Wong, Lilly, Dajiang Li, Yuyang Tang, et al.. (2022). Human Immunodeficiency Virus-1 Latency Reversal via the Induction of Early Growth Response Protein 1 to Bypass Protein Kinase C Agonist-Associated Immune Activation. Frontiers in Microbiology. 13. 836831–836831. 7 indexed citations
10.
Wong, Lilly & Guochun Jiang. (2021). A Plausible Link of TMPRSS2/ACE2/AR Signaling to Male Mortality during the COVID-19 Pandemic in the United States. Pathogens. 10(11). 1378–1378. 1 indexed citations
11.
Narla, Rama Krishna, Hardik Modi, Daniel E. Bauer, et al.. (2021). Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody. Cancer Immunology Immunotherapy. 71(2). 473–489. 29 indexed citations
12.
Wong, Lilly & Guochun Jiang. (2020). NF-κB sub-pathways and HIV cure: A revisit. EBioMedicine. 63. 103159–103159. 33 indexed citations
13.
Goy, André, Vincent Ribrag, Andréa Varga, et al.. (2013). Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM).. Journal of Clinical Oncology. 31(15_suppl). 8522–8522. 7 indexed citations
14.
Venugopalan, Shankar Rengasamy, Lilly Wong, Adriana Cavender, et al.. (2008). Novel expression and transcriptional regulation of FoxJ1 during oro-facial morphogenesis. Human Molecular Genetics. 17(23). 3643–3654. 30 indexed citations
15.
Wong, Lilly, Osamu Miyashita, Meghan T. Miller, et al.. (2005). Coupled Motions in the SH2 and Kinase Domains of Csk Control Src Phosphorylation. Journal of Molecular Biology. 351(1). 131–143. 51 indexed citations
16.
Wong, Lilly, B. Chie-Leon, Osamu Miyashita, et al.. (2004). Dynamic Coupling Between the SH2 Domain and Active Site of the COOH Terminal Src Kinase, Csk. Journal of Molecular Biology. 341(1). 93–106. 39 indexed citations
17.
Boyd, Aileen E., et al.. (2004). Nanosecond Dynamics of Acetylcholinesterase Near the Active Center Gorge. Journal of Biological Chemistry. 279(25). 26612–26618. 24 indexed citations
18.
Rodrı́guez, Juan Carlos, Lilly Wong, & Patricia A. Jennings. (2003). The solvent in CNBr cleavage reactions determines the fragmentation efficiency of ketosteroid isomerase fusion proteins used in the production of recombinant peptides. Protein Expression and Purification. 28(2). 224–231. 16 indexed citations
19.
Hamuro, Yoshitomo, Lilly Wong, Jennifer Shaffer, et al.. (2002). Phosphorylation Driven Motions in the COOH-terminal Src Kinase, Csk, Revealed Through Enhanced Hydrogen–Deuterium Exchange and Mass Spectrometry (DXMS). Journal of Molecular Biology. 323(5). 871–881. 70 indexed citations
20.
Taylor, Palmer, Lilly Wong, Zoran Radić, et al.. (1999). Analysis of cholinesterase inactivation and reactivation by systematic structural modification and enantiomeric selectivity. Chemico-Biological Interactions. 119-120. 3–15. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026